Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | RGS12 | O14924 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL7951771 | 0.98 | CA2 (0.69) | CA2KDM4ETSHRMAPTHPGD | |
| Hydrochloric Acid SCHEMBL2530252 | 0.98 | CA2 (0.69) | CA2KDM4ETSHRMAPTHPGD | |
| Methyl Alcohol SCHEMBL7045180 | 0.96 | CA2 (0.67) | CA2KDM4ETSHRMAPTHPGD | |
| SCHEMBL11361475 | 0.88 | HAO1 (0.58) | CA2KDM4ETSHRMAPTHPGD | |
| SCHEMBL377506 | 0.83 | CA2 (1.00) | CA2KDM4ETSHRMAPTHPGD | |
| SCHEMBL11859884 | 0.83 | CA2 (0.67) | CA2KDM4ETSHRMAPTHPGD | |
| SCHEMBL585295 | 0.83 | CA2 (0.72) | CA2KDM4ETSHRMAPTHPGD | |
| SCHEMBL2164422 | 0.83 | HAO1 (0.57) | CA2KDM4ETSHRBLMPIK3CA | |
| SCHEMBL659220 | 0.83 | PIK3CA (0.54) | CA2TSHRPIK3CAKMT2AIDO1 | |
| SCHEMBL1245996 | 0.82 | CA2 (0.59) | CA2KDM4ETSHRMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283659-B | Preparation method and application of m-nitrobenzonitrile | 上海忝晴化工有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-114994196-B | High performance liquid chromatography separation method for guanfacine hydrochloride intermediate 2, 6-dichlorophenylacetic acid and impurities | 上海应用技术大学 | 2024-12-31 | — | — | CN | claimed |
| CN-114671781-B | Method for converting arylbenzylamine into arylnitrile compound | 南通大学 | 2024-04-19 | — | — | CN | claimed |
| CN-116283659-A | Preparation method and application of m-nitrobenzonitrile | 上海忝晴化工有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-112063005-B | Preparation method of molecular imprinting integral needle type extraction device for enriching polychlorinated biphenyl | 吉林化工学院 | 2022-12-06 | — | — | CN | claimed |
| CN-114671781-A | Method for efficiently converting arylbenzylamine into aryl nitrile compound | 南通大学 | 2022-06-28 | — | — | CN | claimed |
| CN-114478122-A | Novel functional fertilizer synergist and application | 郑州郑氏化工产品有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-109535080-B | Synthesis method of benzimidazole derivative | 广东省石油与精细化工研究院 | 2021-01-01 | — | — | CN | claimed |
| CN-112063005-A | Preparation method of molecular imprinting integral needle type extraction device for enriching polychlorinated biphenyl | 吉林化工学院 | 2020-12-11 | — | — | CN | claimed |
| EP-3097084-B1 | NEW KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2020-09-30 | — | — | EP | claimed |
| EP-2411375-A1 | PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5 TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION | Poxel (FR) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109015-A1 | PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5 TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION | POXEL (FR) | 2010-09-30 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | CA2 32/4885KDM4E 1814/4885TSHR 2894/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | CA2 664/4885KDM4E 1567/4885TSHR 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.